Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

168results about "Plant genotype modification" patented technology

Methods for the diagnosis, prognosis and treatment of metabolic syndrome

InactiveUS20060211020A1Sugar derivativesPeptide/protein ingredientsPhosphatidate cytidylyltransferaseGlycerol kinase
The present invention provides methods for detecting susceptibility to metabolic syndrome. In particular, the presence of differences in at least one of the following genes; microsomal triglyceride transfer protein (MTP), fatty acid binding protein 2 (FABP2), annexin A5 (ANXA5), pyruvate dehydrogenase (lipoamide) alpha 2 (PDHA2), CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 (CDS 1), and glycerol kinase 2 (GK2) serves as a prognostic and diagnostic indicator of metabolic syndrome. Furthermore, metabolic syndrome can be treated by regulating the levels of MTP, FABP2, ANXA5, PDHA2, CDS1, and GK2.
Owner:TRUSTEES OF BOSTON UNIV

Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling

InactiveUS7247618B2Sure easySuppression problemBiocideNervous disorderMammalSignalling pathways
Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administers to a mammal viral vectors that deliver genes experessing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis.
Embodiments of the present invention are directed primarily, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF signaling through its receptor. Pathobiologic phenomena include, but are not limited to, disease entities such as osteoporosis, Alzheimer's disease, diabetes mellitus (Type 1 and/or Type 2), infectious diseases, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.
Owner:RAJAVASHISTH TRIPATHI

Method and circuit arrangement for treating biomaterial

ActiveUS20060094095A1Successful cell treatmentAvoid and offsetBioreactor/fermenter combinationsBiological substance pretreatmentsElectricityVoltage pulse
The invention relates to a method for treating biomaterial using at least one electrical field generated by a first voltage pulse which is terminated once the value for an electrical parameter has exceeded or dropped below a preset limit. After the first voltage pulse has been terminated, it is continued by an additional voltage pulse. The invention also relates to a circuit arrangement comprising at least one storage device for electrical charges to generate at least one voltage pulse by selectively discharging the storage device, and at least one control unit for controlling the discharge. The present invention provides a controller for monitoring the chronological progression of the voltage pulse, said controller controlling at least one continuation of discharge after termination.
Owner:LONZA COLOGNE AG

Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob

InactiveUS7297542B2Efficient transductionRaise transfer toBiocideAntibody mimetics/scaffoldsHeterologousEpitope
The present invention provides means to modify the tropism of recombinant adenoviral vectors using genetic methods to alter the adenoviral fiber cell-binding protein. The present invention generates an adenovirus with modified fiber gene such that novel tropism is achieved. This recombinant adenovirus has a fiber gene modified in the HI loop domain.
Owner:UAB RES FOUND

Blowing pollinator and method for using same to carry out blowing pollination

The invention relates to the field of cross breeding, in particular to a blowing pollinator and a method for using the same to carry out blowing pollination. The blowing pollinator comprises a fan and an air guide; the air outlet of the fan is connected with the air guide, and the air outlet end of the air guide is connected with two air nozzles; each air nozzle is an adjustable air nozzle, and can adjust the angle between the jetted airflow and the horizontal plane; each air nozzle is perpendicular to the air outlet end of the air guide, i.e., the flowing direction is changed by 90 degrees after the airflow enters the air nozzle via the air guide; the two air nozzles respectively face up at the left and the right of the air outlet end of the air guide; and the fan is connected with a storage battery for supplying power and a flow velocity regulator for regulating the velocity of the airflow. The blowing pollinator and the blowing pollination method provided by the invention can utilize the airflow to directly blow the mature pollen of male parents into the air over a male parent area, the pollen then spontaneously falls to finish the pollination process, and thereby the setting rate of the cross breeding can be remarkably increased.
Owner:SICHUAN CHUANLONG TRACTORS MFG CO LTD

Treatment of neurodegenerative diseases by targeting mirna

ActiveUS20130184331A1Inhibit functioningImprove regenerative abilityOrganic active ingredientsNervous disorderMedicinePharmaceutical drug
The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases by targeting a specific miRNA. In addition, the present invention relates to a kit for diagnosing neurodegenerative diseases. A miR-206 target found in the present invention, which is highly expressed in both animal models of Alzheimer's disease and human brain samples, is a substantial treatment target selected without artifact errors. An antisense oligonucleotide of the present invention as an inhibitor for miR-206 suggests a successful result in treatment of neurodegenerative diseases by targeting miRNA. The antisense oligonucleotide of the present invention inhibits the function of miR-206 to greatly increase the levels of BDNF and IGF-1 and to increase the regeneration of synapses, thereby treating neurodegenerative diseases, particularly Alzheimer's disease.
Owner:SEOUL NAT UNIV R&DB FOUND

Method for performing cross breeding on water chestnut and Dongkui waxberry for waxberry cultivating variety

ActiveCN104026001AAchieve hybridizationWidely used in germplasm innovationPlant genotype modificationWater ChestnutsGenotype determination
The invention discloses a method for performing cross breeding on water chestnut and Dongkui waxberry for waxberry cultivating variety. The method comprises the following steps: by taking water chestnut as a female parent and taking male flower of Dongkui waxberry as a male parent, pollinating during water chestnut full-blossom period; collecting seeds after the fruits are ripened, storing the seeds at the temperature of 5 DEG C, seeding to obtain F1 plants; and screening true hybrid plants from the F1 plants. Intervarietal cross breeding between the waxberry cultivating varieties such as water chestnut and Dongkui waxberry is realized for the first time, true hybrid plants with certain genotypes are obtained, and a novel technological approach is provided for breeding novel waxberry variety. Moreover, the filial generation is subjected to hybrid identification by amplifying specific expression SSR markers of the F1 generation, the identification process is simple and rapid and the cost is low, the identification result is stable and reliable, and the gap of the molecular biological identification technology of waxberry intervarietal hybridization is filled.
Owner:ZHEJIANG UNIV +1

Artificial synthesised scorpion chloride ion neurotoxin gene-rBmK CTa

InactiveCN1597951ASugar derivativesPeptide/protein ingredientsEscherichia coliDisease
The invention makes 24-site mutation on natural scorpion chlorine ion channel neurotoxin gene BmK CT according to the principle of Escherichia coli partial to codon, designs DNA sequence suitable to be expressed in Escherichia coli BL21 (DE3), adopts PCR technique to complete artificial synthesis of recombinant scorpion chlorine ion channel neurotoxin gene rBmK CTa. On this basis, it clones rBmK CTa into pEXSecI expression system to transfer in the BL21 (DE3), screens and obtains high-performance expressed bacterial strain, detects that the expressed product of the rBmK CTa accounts for 19.936% of the all-bacterium protein by SDS-PAGE electrophoresis, and by affinity chromatography, obtains purer protein with bioactivity, and can obtain 2.4mg protein from one liter culture liquor by purifying. The obtained modified recombinant scorpion chlorine ion channel neurotoxin has inhibition effect on neuroglia cell and can be used in preparing medicines curing diseases by inhibiting neuroglia cell and also be used in research on the space structure and pharmacological activity of scorpion neurotoxin.
Owner:SHANXI UNIV

Plants and seeds of hybrid corn variety CH744817

According to the invention, there is provided seed and plants of the hybrid corn variety designated CH744817. The invention thus relates to the plants, seeds and tissue cultures of the variety CH744817, and to methods for producing a corn plant produced by crossing a corn plant of variety CH744817 with itself or with another corn plant, such as a plant of another variety. The invention further relates to genetic complements of plants of variety CH744817.
Owner:MONSANTO TECH LLC

Inbred corn line D601

An inbred corn line, designated D601, is disclosed. The invention relates to the seeds of inbred corn line D601, to the plants of inbred corn line D601 and to methods for producing a corn plant, either inbred or hybrid, by crossing the inbred line D601 with itself or another corn line. The invention further relates to methods for producing a corn plant containing in its genetic material one or more transgenes and to the transgenic plants produced by that method and to methods for producing other inbred corn lines derived from the inbred D601.
Owner:CENT GOLDEN HARVEST RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products